-- Safety Endpoint for TRC Product Reached; Trial Expanded --

Aastrom Biosciences Announces Appointment of Janet M. Hock, B.D.S., Ph.D. As Vice President Global Research Ann Arbor, Michigan, September 14, 2004 -- Aastrom Biosciences, Inc. (NasdaqSC: ASTM) today announced the appointment of Janet M. Hock, B.D.S., Ph.D. as Vice President Global Research. Dr.

-- Long-Term CEO and Chairman to Continue at Board Level --

-- Aastrom's Proprietary Technology Used to Produce Therapeutic Quantities of T-Cells --

Aastrom Biosciences CEO to Present at Rodman & Renshaw Techvest 6th Annual Healthcare Conference Ann Arbor, Michigan, October 25, 2004 -- Aastrom Biosciences, Inc. (NasdaqSC: ASTM) announced today R. Douglas Armstrong, Ph.D., Chairman and Chief Executive Officer, will present at the Rodman &

Aastrom Biosciences CEO to Present at Rodman & Renshaw Techvest 7th Annual Healthcare Conference Ann Arbor, Michigan, November 3, 2005 -- Aastrom Biosciences, Inc. (Nasdaq: ASTM) announced today R. Douglas Armstrong, Ph.D., Chairman and Chief Executive Officer, will present at the Rodman & Renshaw

-- Final $12 Million Tranche Completed at Premium to Market --

-- Phase II Grant to Support Bone Formation and Vascularization Capabilities of Company's Tissue Repair Cells --

Aastrom Biosciences to Hold Investor Conference Call Tomorrow Ann Arbor, Michigan, April 28, 2004 -- Aastrom Biosciences, Inc. (NasdaqSC: ASTM) announced today that it will hold an investor conference call tomorrow, Thursday, April 29, 2004 at 11:00 a.m. (EDT).

Herbert S. Schwartz, M.D. Appointed to Aastrom Biosciences' Technology Review Board Ann Arbor, Michigan, October 14, 2003 -- Aastrom Biosciences, Inc. (NasdaqSC: ASTM) today announced the appointment of Herbert S. Schwartz, M.D. to its Technology Review Board (TRB). Dr.